Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein ...

Oral presentation will highlight previously reported data demonstrating early stabilization or improvement in mFARS scores ...

Another potential blockbuster just joined AbbVie's drug portfolio.

Vima Therapeutics, a clinical-stage biotechnology company focused on oral therapies for movement disorders, today announced that four poster presentations will be featured at the 2026 International ...

Parkinson’s disease is a brain disorder that gradually affects movement and many other body functions. It develops as nerve ...

Tavapadon, a treatment for Parkinson’s disease recently approved by the FDA, provides a novel option for healthcare providers ...

Poster Title: Long-Term Open-Label Data on the GCase Modulator GT-02287 ( Rexaceract) in People with Parkinson’s Disease Location : Hall D, 3 rd Floor, E-Poster Station 12 The International Parkinson ...

The annual POP Walk (People of Parkinson's) is happening on Saturday, October 3rd at First Baptist Church of Augusta ...

Two devastating movement disorders, Parkinson’s disease and multiple system atrophy, often look so similar in the clinic that ...

H. Lundbeck A/S (Lundbeck) announced that data from its movement disorders pipeline will be presented at the International Congress of Parkinson's disease and Movement Disorders® (MDS) 2026, taking ...

Neuroscience imaging company IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB) has presented new research at a European conference ...

The FDA has approved Juvmo, the first and only dopamine agonist for adults with Parkinson’s disease designed to selectively ...